Evidence map›Paper›PMID 42028144›Full record

ReviewJournal of intensive medicine2026

Itaconate modifications: Mechanisms and applications.

Yingyi Yang, Rui Kang, Huiting Zhou, Daolin Tang

Abstract readReview
In one paragraph

Review in Journal of intensive medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Itaconate metabolism in regulated cell death.Molecular and cellular biochemistry · 2026
    Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Yingyi YangDepartment of Surgery, UT Southwestern Medical Center, Dallas, TX, USA.
Rui KangDepartment of Surgery, UT Southwestern Medical Center, Dallas, TX, USA.
Huiting ZhouInstitute of Pediatric Research, Children's Hospital of Soochow University, Suzhou, Jiangsu, China.
Daolin TangDepartment of Surgery, UT Southwestern Medical Center, Dallas, TX, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Itaconate is a mitochondrial metabolite generated from the tricarboxylic acid cycle intermediate cis-aconitate by the enzyme aconitate decarboxylase 1 (ACOD1). Beyond its metabolic role, itaconate has emerged as a critical regulator of immune and inflammatory signaling. Together with its electrophilic derivatives (e.g., 4-octyl itaconate, dimethyl itaconate), it modulates diverse cellular processes through covalent post-translational modifications. These include S-itaconation, a cysteine-directed Michael addition primarily mediated by electrophilic derivatives, and K-itaconation, a lysine-targeted, reversible acylation involving an itaconyl-CoA intermediate derived from itaconate. Such modifications influence multiple immune regulators - including Kelch-like ECH-associated protein 1 (KEAP1), stimulator of interferon response cGAMP interactor 1 (STING1), NLR family pyrin domain containing 3 (NLRP3), glutathione peroxidase 4 (GPX4), and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) - thereby modulating inflammation, oxidative stress, and cell death pathways such as pyroptosis and ferroptosis. Preclinical studies demonstrate that itaconate derivatives confer therapeutic benefits in sepsis, colitis, neurodegeneration, autoimmunity, and cancer. By contrast, endogenous itaconate exhibits context-dependent effects, acting as either a pro-resolving or immunostimulatory metabolite. This review integrates current insights into itaconate biosynthesis, molecular targets, post-translational modifications, detection technologies, and translational potential, underscoring its emerging role as a master regulator of immunometabolic reprogramming and inflammatory control.

Indexed as

ACOD1Disease pathogenesisInflammationItaconateItaconation

Identifiers

PMID42028144
PMCPMC13100862

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.